Cargando…

Dapagliflozin improves treatment satisfaction in overweight patients with type 2 diabetes mellitus: a patient reported outcome study (PRO study)

BACKGROUND: The benefits of sodium glucose cotransporters 2 (SGLT2) inhibitors in patients with type 2 diabetes mellitus include plasma glucose control, reduction in body weight and blood pressure, and low risk of hypoglycemia, although they may also cause genitourinary infections, polyuria, or volu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nakajima, Hiroki, Okada, Sadanori, Mohri, Takako, Kanda, Eiichiro, Inaba, Naoyuki, Hirasawa, Yoko, Seino, Hiroaki, Kuroda, Hisamoto, Hiyoshi, Toru, Niiya, Tetsuji, Ishii, Hitoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5831584/ https://www.ncbi.nlm.nih.gov/pubmed/29507611 http://dx.doi.org/10.1186/s13098-018-0313-x

Ejemplares similares

Quality-of-Life Comparison of Dapagliflozin Versus Dipeptidyl Peptidase 4 Inhibitors in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial (J-BOND Study)
por: Ishii, Hitoshi, et al.
Publicado: (2020)

Improvement of quality of life through glycemic control by liraglutide, a GLP-1 analog, in insulin-naive patients with type 2 diabetes mellitus: the PAGE1 study
por: Ishii, Hitoshi, et al.
Publicado: (2017)

Development of a self‐efficacy questionnaire, ‘Insulin Therapy Self‐efficacy Scale (ITSS)’, for insulin users in Japanese: The Self‐Efficacy‐Q study
por: Nakaue, Junko, et al.
Publicado: (2018)

Adrenal Crisis Associated With COVID-19 Vaccination in Patients With Adrenal Insufficiency
por: Kurematsu, Yukako, et al.
Publicado: (2023)

Correction to: Reproducibility and Validity of a Questionnaire Measuring Treatment Burden on Patients with Type 2 Diabetes: Diabetic Treatment Burden Questionnaire (DTBQ)
por: Ishii, Hitoshi, et al.
Publicado: (2018)

Reproducibility and Validity of a Questionnaire Measuring Treatment Burden on Patients with Type 2 Diabetes: Diabetic Treatment Burden Questionnaire (DTBQ)
por: Ishii, Hitoshi, et al.
Publicado: (2018)

Risk of Lactic Acidosis in Hospitalized Diabetic Patients Prescribed Biguanides in Japan: A Retrospective Total-Population Cohort Study
por: Mohri, Takako, et al.
Publicado: (2023)

Treatment Burden on Once-Weekly Omarigliptin Versus Daily Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes: Randomized Controlled Trial (ONWARD-DPP4 Study)
por: Ishii, Hitoshi, et al.
Publicado: (2023)

Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR)
por: Fuchigami, Ayako, et al.
Publicado: (2020)

Adrenal insufficiency in immunochemotherapy for small-cell lung cancer with ectopic ACTH syndrome
por: Nakajima, Hiroki, et al.
Publicado: (2021)

Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study
por: Shigiyama, Fumika, et al.
Publicado: (2017)

Dapagliflozin rescues endoplasmic reticulum stress-mediated cell death
por: Shibusawa, Ryo, et al.
Publicado: (2019)

Insulin dose reduction in dapagliflozin combination therapy for type 1 diabetes mellitus: the RISING-STAR study
por: Hamaguchi, Masahide, et al.
Publicado: (2022)

Dapagliflozin Inhibits Cell Adhesion to Collagen I and IV and Increases Ectodomain Proteolytic Cleavage of DDR1 by Increasing ADAM10 Activity
por: Okada, Junichi, et al.
Publicado: (2020)

Absolute risk of acute coronary syndrome after severe hypoglycemia: A population‐based 2‐year cohort study using the National Database in Japan
por: Nishioka, Yuichi, et al.
Publicado: (2019)

Association between influenza and the incidence rate of new‐onset type 1 diabetes in Japan
por: Nishioka, Yuichi, et al.
Publicado: (2021)

A Comparison of the Pharmacokinetics and Safety of Dapagliflozin Formate, an Ester Prodrug of Dapagliflozin, to Dapagliflozin Propanediol Monohydrate in Healthy Subjects
por: Kim, Hyun Chul, et al.
Publicado: (2023)

Rationale and Design of the STOP-OB Study for Evaluating the Effects of Tofogliflozin and Glimepiride on Fat Deposition in Type 2 Diabetes Patients Treated with Metformin/DPP-4 Inhibitor Dual Therapy
por: Ishihara, Hisamitsu, et al.
Publicado: (2018)

Comparison of tofogliflozin versus glimepiride as the third oral agent added to metformin plus a dipeptidyl peptidase‐4 inhibitor in Japanese patients with type 2 diabetes: A randomized, 24‐week, open‐label, controlled trial (STOP‐OB)
por: Kitazawa, Toru, et al.
Publicado: (2020)

Longitudinal impact of dapagliflozin treatment on ventricular repolarization heterogeneity in patients with type 2 diabetes
por: Sato, Tatsuya, et al.
Publicado: (2019)

Unexpected association between subclinical hearing loss and restorative sleep in a middle-aged and elderly Japanese population
por: Nakajima, Kei, et al.
Publicado: (2018)

The effect of dapagliflozin treatment on epicardial adipose tissue volume
por: Sato, Takao, et al.
Publicado: (2018)

Characteristics of Dapagliflozin Responders: A Longitudinal, Prospective, Nationwide Dapagliflozin Surveillance Study in Korea
por: Han, Eugene, et al.
Publicado: (2018)

Changes in glycemic control and skeletal muscle mass indices after dapagliflozin treatment in individuals with type 1 diabetes mellitus
por: Yoshimura, Yuta, et al.
Publicado: (2023)

Incidence and seasonality of type 1 diabetes: a population-based 3-year cohort study using the National Database in Japan
por: Nishioka, Yuichi, et al.
Publicado: (2020)

Not so critical appraisal of dapagliflozin
por: Doggrell, Sheila A
Publicado: (2014)

Subclinical Hearing Loss, Longer Sleep Duration, and Cardiometabolic Risk Factors in Japanese General Population
por: Nakajima, Kei, et al.
Publicado: (2014)

Alcohol and Exercise Affect Declining Kidney Function in Healthy Males Regardless of Obesity: A Prospective Cohort Study
por: Kanda, Eiichiro, et al.
Publicado: (2015)

Effects of Weight Loss Speed on Kidney Function Differ Depending on Body Mass Index in Nondiabetic Healthy People: A Prospective Cohort
por: Kanda, Eiichiro, et al.
Publicado: (2015)

Appropriate definition of diabetes using an administrative database: A cross‐sectional cohort validation study
por: Nishioka, Yuichi, et al.
Publicado: (2021)

Dapagliflozin: BMS 512148; BMS-512148
Publicado: (2012)

An exploration of the experience of dapagliflozin in clinical practice
por: Anitha, Anuba Paulvarnan, et al.
Publicado: (2022)

A Nonlinear Mixed Effects Pharmacokinetic Model for Dapagliflozin and Dapagliflozin 3-O-glucuronide in Renal or Hepatic Impairment
por: van der Walt, J-S, et al.
Publicado: (2013)

Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add‐on to metformin in patients with type 2 diabetes
por: Müller‐Wieland, Dirk, et al.
Publicado: (2018)

Uric Acid Level Has a U-Shaped Association with Loss of Kidney Function in Healthy People: A Prospective Cohort Study
por: Kanda, Eiichiro, et al.
Publicado: (2015)

Scoliosis surgery for handicapped children
por: Nakamura, Naoyuki, et al.
Publicado: (2017)

Dapagliflozin-Induced Acute-on-Chronic Liver Injury
por: Levine, Joshua A., et al.
Publicado: (2016)

Dapagliflozin: A Review in Type 2 Diabetes
por: Dhillon, Sohita
Publicado: (2019)

Dapagliflozin: A Review in Type 1 Diabetes
por: Paik, Julia, et al.
Publicado: (2019)

The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58
por: Mosenzon, Ofri, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_d9ra20a5r8vj9ld8jtf3rj7e0e